News

Theratechnologies FDA Rejection

1 Mins read

Theratechnologies is poised for a significant setback as the Food and Drug Administration (FDA) has rejected its supplemental biologics license application for an intramuscular method of administering a maintenance dose of Trogarzo, an HIV-1 inhibitor.

Stock Performance

In premarket trading on Nasdaq, Theratechnologies shares were down by 30%, following a 1.2% increase in 2024, closing at $1.64 in the previous session. Similarly, in Toronto, the shares closed at C$2.20, reflecting a 2.8% gain in the new year.

FDA’s Decision

The biopharmaceutical company received a refusal to file letter from the FDA regarding its supplemental license application. The FDA cited that the application lacked completeness for a substantive review. Particularly, it mentioned the absence of essential data required to establish the pharmacokinetic bridge between the intramuscular and intravenous infusion route of administration of Trogarzo.

Company Response

Commenting on the FDA’s decision, Christian Marsolais, Theratechnologies’ chief medical officer, expressed disappointment but acknowledged the challenges based on the TMB-302 study results from October 2023. He stated, “We will now assess our options regarding this application.”

Theratechnologies now faces uncertainties concerning the future of its sBLA for Trogarzo’s intramuscular administration.

Related posts
News

$TRUMP and other meme coins won't be protected by SEC, Commissioner Hester Peirce says

3 Mins read
LAS VEGAS — Now that the SEC is out of the business of regulating meme coins, investors shouldn’t expect any guidance on…
News

Man charged in New York with 3-week kidnapping to try to steal Bitcoin

1 Mins read
NEW YORK (Reuters) -A grand jury has indicted a 37-year-old cryptocurrency investor accused of kidnapping a business partner inManhattan’s upscale Soho neighborhood…
News

Goldman Sachs Expert Predicts Significant Gold Price Surge by 2026

2 Mins read
Investors are advised to consider risk-reward balance and portfolio diversification.Trending NowBest Forex Trading Robots To Invest In 2022 Daan Struyven, co-head of…

Leave a Reply

Your email address will not be published. Required fields are marked *

72 − = 67